NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its second quarter revenues rose 172 percent year over year, driven by a 149 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended June 30, the molecular diagnostics company reported revenues of $57.6 million, up from $21.2 million a year earlier, and significantly beating analysts' consensus estimate of $49.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.